Skip to Content
Merck
All Photos(1)

Documents

387A

Sigma-Aldrich

Leukocyte Acid Phosphatase (TRAP) Kit

Kit formulated with all liquid reagents

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352106
eCl@ss:
42010102
NACRES:
NA.47

Quality Level

shelf life

Expiry date on the label.

IVD

for in vitro diagnostic use

application(s)

hematology
histology

shipped in

wet ice

storage temp.

2-8°C

Principle

Peripheral blood or bone marrow preparations are fixed to a microscope slide. The resulting film is incubated in a solution of Naphthol AS-BI phosphoric acid and freshly diazotized Fast Garnet GBC. Kit is used to demonstrate acid phosphatase and tartrate resistant acid phosphatase (TRAP) in blood, bone marrow and tissue touch preparations.

Kit Components Only

Product No.
Description

  • Hematoxylin Solution, Gill No. 3 (kit only) 50 mL

Kit Components Also Available Separately

Product No.
Description
SDS

  • 3863Acetate Solution, 2.5 M, pH 5.2 50 mLSDS

  • 915Citrate Solution, pH 3.6±0.1 (25 °C), 27 mM 50 mLSDS

  • 3872Fast Garnet GBC Base Solution 10 mLSDS

  • 3871Naphthol AS-BI Phosphoric Acid Solution 10 mLSDS

  • 914Sodium nitrite solution 10 mLSDS

  • 3873Tartrate Solution 10 mLSDS

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Carc. 1B - Eye Dam. 1 - Met. Corr. 1 - Skin Corr. 1B - STOT RE 2 Oral

Target Organs

Kidney

WGK

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yun Zhang et al.
Biological & pharmaceutical bulletin, 39(12), 2028-2035 (2016-12-03)
Osteolysis induced by chronic Gram-negative bacterial infection underlies many bone diseases such as osteomyelitis, septic arthritis, and periodontitis. Drugs that inhibit lipopolysaccharide (LPS)-induced osteolysis are critically needed for the prevention of bone destruction in infective bone diseases. In this study
L Wei et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 25(8), 2089-2096 (2014-05-09)
Recently, the use of the pharmacological agent strontium ranelate has come to prominence for the treatment of osteoporosis. While much investigation is focused on preventing disease progression, here we fabricate strontium-containing scaffolds and show that they enhance bone defect healing
Jihai Wang et al.
Frontiers in pharmacology, 9, 64-64 (2018-02-24)
Lipopolysaccharide (LPS) can induce bone loss by stimulating bone resorption. Natural compounds have great potential for the treatment of osteolytic bone diseases. Magnesium lithospermate B (MLB) plays an important role in protecting against oxidative damage and also has potential anti-inflammatory
Huey-En Tzeng et al.
Scientific reports, 8(1), 11190-11190 (2018-07-27)
NC-8 (ent-16-oxobeyeran-19-N-methylureido) is an isosteviol-derived analogue with multiple biological effects, including anti-inflammation and anti-bacterial activities and inhibition of HBV viral surface antigen gene expression. In this study, we explored the effects of NC-8 on the formation of osteoclasts from RAW
Nan Shang et al.
Nutrients, 11(9) (2019-09-25)
Ovotransferrin, a member of the transferrin family, is the second main protein found in egg white. Ovotransferrin was reported to have antimicrobial, antioxidant, and immunomodulating activities. The aim of this work was to characterize the cellular and molecular functions of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service